Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 11, 2011, Pages 1638-1645

  Chung, Goh Eun ^a,b   Kim, Won ^b   Lee, Jeong Hoon ^b   Kim, Yoon Jun ^b   Yoon, Jung Hwan ^b   Lee, Jeong Min ^b   Lee, Jae Young ^b   Kim, Se Hyung ^b   Kim, Donghee ^a   Lee, Hyo Suk ^b  

^a Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Ablation; Hepatitis B envelope antigen; Hepatitis B virus DNA; Hepatocellular carcinoma; Recurrence

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS B(E) ANTIGEN;

ABLATION THERAPY; ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RISK FACTOR; TUMOR RECURRENCE; VIRUS LOAD;

EID: 80054942485     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06777.x     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J etal. Estimating the world cancer burden: globocan 2000. Int. J. Cancer 2001; 94: 153-6.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999; 340: 745-50.
3. Leykum LK, El-Serag HB, Cornell J etal. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin. Gastroenterol. Hepatol. 2007; 5: 508-12.
4. McMahon BJ, Bulkow L, Harpster A etal. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32: 842-6.
5. Oka H, Kurioka N, Kim K etal. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12: 680-7.
6. Fong Y, Sun RL, Jarnagin W etal. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann. Surg. 1999; 229: 790-9.
7. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
8. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
9. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
10. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001; 35: 421-30.
11. Bruix J, Castells A, Bosch J etal. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-22.
12. Okada S. Local ablation therapy for hepatocellular carcinoma. Semin. Liver Dis. 1999; 19: 323-8.
13. Chen MS, Li JQ, Zheng Y etal. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg. 2006; 243: 321-8.
14. Nakashima O, Kojiro M. Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J. Hepatobiliary Pancreat. Surg. 2001; 8: 404-9.
15. Pawlik TM, Delman KA, Vauthey JN etal. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005; 11: 1086-92.
16. Hung IF, Poon RT, Lai CL etal. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am. J. Gastroenterol. 2008; 103: 1663-73.
17. Kim BK, Park JY, Kim do Y etal. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int. 2008; 28: 393-401.
18. Poon RT, Fan ST, Ng IO etal. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-7.
19. Imamura H, Matsuyama Y, Tanaka E etal. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 2003; 38: 200-7.
20. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual, 6th edn. New York: Springer, 2002; xiv 421.
21. Wu JC, Huang YH, Chau GY etal. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J. Hepatol. 2009; 51: 890-7.
22. Chuma M, Hige S, Kamiyama T etal. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J. Gastroenterol. 2009; 44: 991-9.
23. Wang C, Lu Y, Chen Y etal. Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. Clin. Exp. Metastasis 2009; 26: 839-48.
24. Choi GH, Kim DH, Choi SB etal. The preoperative positivity for serum hepatitis B e antigen did not affect overall survival after curative resection of hepatitis B virus-related hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2009; 24: 391-8.
25. Sun HC, Zhang W, Qin LX etal. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J. Hepatol. 2007; 47: 684-90.
26. Chen JH, Chau GY, Lui WY etal. Surgical results in patients with hepatitis B-related hepatocellular carcinoma and positive hepatitis B early antigen. World J. Surg. 2000; 24: 383-7.
27. Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J. Hepatol. 2010; 52: 594-604.
28. Hino O, Shows TB, Rogler CE. Hepatitis B virus integration site in hepatocellular carcinoma at chromosome 17;18 translocation. Proc. Natl. Acad. Sci. USA 1986; 83: 8338-42.
29. Zhou YZ, Slagle BL, Donehower LA etal. Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma. J. Virol. 1988; 62: 4224-31.
30. Carman WF, Jacyna MR, Hadziyannis S etal. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91.
31. Akahane Y, Yamanaka T, Suzuki H etal. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990; 99: 1113-9.
32. Liu S, Zhang H, Gu C etal. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J. Natl. Cancer Inst. 2009; 101: 1066-82.
33. Yang HI, Yeh SH, Chen PJ etal. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl. Cancer Inst. 2008; 100: 1134-43.
34. Zhong S, Chan JY, Yeo W etal. Frequent integration of precore/core mutants of hepatitis B virus in human hepatocellular carcinoma tissues. J. Viral. Hepat. 2000; 7: 115-23.
35. Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology 2005; 48: 133-7.